Product Datasheet

AZD-4635

Catalog No. **BP-01868** · CAS **1321514-06-0** · Form **free base** · Physical state **solid** · Color **Off-white to yellow** · Version **1.0** · Revision **2026-09-07**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Adenosine Receptor	**Cancer**

Molecular formula	$C_{15}H_{11}ClFN_5$
Molecular weight	**315.7330**

STRUCTURE



DESCRIPTION

Imaradenant (AZD4635, HTL1071) is an oral A2AR antagonist that binds to human A2AR with a Ki of 1.7 nM and with > 30-fold selectivity over other adenosine receptors.

BIOLOGICAL ACTIVITY

In Vitro
In the presence of 0.1, 1 and 10 μM adenosine, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM, respectively.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Jazayeri A, Andrews SP, Marshall FH. Structurally Enabled Discovery of Adenosine A(2A) Receptor Antagonists. Chem Rev. 2017 Jan 11;117(1):21-37. doi:10.1021/acs.chemrev.6b00119. Epub 2016 Jun 22. Review. PubMed PMID: 27333206.

[2]. Alexandra Borodovsky, et al. Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression. AACR Cancer Res. 2017, 77(13 Suppl):Abstract nr 5580.